US Tech 100

17,617.63

0.04%

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

AIM AIM ImmunoTech Inc

0.435

0.015 (3.57%)

May 07 2024 - Closed

Delayed by 15 minutes

Form D/A - Notice of Exempt Offering of Securities: [Amend]

AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more AIM ImmunoTech Charts.

AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From May 2023 to May 2024

AIM ImmunoTech Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 7 May 2024 (15 hours ago) • Edgar (US Regulatory)

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
Monday 6 May 2024 (2 days ago) • GlobeNewswire Inc.

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Monday 29 April 2024 (1 week ago) • GlobeNewswire Inc.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Thursday 25 April 2024 (2 weeks ago) • GlobeNewswire Inc.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Thursday 18 April 2024 (3 weeks ago) • GlobeNewswire Inc.

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
Monday 15 April 2024 (3 weeks ago) • GlobeNewswire Inc.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Thursday 11 April 2024 (4 weeks ago) • GlobeNewswire Inc.

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Wednesday 10 April 2024 (4 weeks ago) • GlobeNewswire Inc.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Thursday 28 March 2024 (1 month ago) • GlobeNewswire Inc.

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

More AIM ImmunoTech Inc News Articles

Globestar Therapeutics (PK)

Therapeutic Solutions (PK)

USOTC

RXMD

Progressive Care (QB)

Digital Brand Media and ... (PK)

USOTC

TPTW

TPT Global Tech (CE)

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AIM AIM ImmunoTech Inc

AIM ImmunoTech Inc News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AIM AIM ImmunoTech Inc

AIM ImmunoTech Inc News

Your Recent History

Company

Business

Popular

Get The App